Home/ Stocks/ PTHS

Pelthos Therapeutics Inc.

PTHS XASE

$25.50 +0.46 (+1.86%) ▲ 15-min delayed

Open

$25.16

High

$25.67

Low

$24.63

Volume

14.4K

Market Cap

$85.55M

About Pelthos Therapeutics Inc.

Pelthos Therapeutics Inc is a biopharmaceutical company committed to commercializing safe and efficacious therapeutic products to help patients with unmet treatment burdens. The Company currently has three U.S. Food and Drug Administration (FDA) approved products in its commercial portfolio, in various stages of commercialization, including ZELSUVMITM, XEPI, and XEGLYZE. The company operates in two reporting segments: the sale, promotion, and commercialization of approved commercial products, the Commercial Operations segment, and research and development activities related to developing a novel and proprietary class of NaV blockers that target the body's peripheral nervous system; and supportive activities to expand the NITRICIL nitric oxide-based technology.

Sector: BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) Employees: 92 Website →

Key Financials

Period	Revenue	Net Income	EPS
TTM 2025	$16.80M	$-43,319,000	$-23.04
FY 2025	$16.80M	$-43,319,000	$-23.04
Q3 2025	$7.41M	$-16,238,000	$-5.30

Related Market News

No specific coverage for PTHS yet. Check out our latest market news or earnings calendar.

Get PTHS Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Pelthos Therapeutics Inc..

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.